Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients

被引:4
作者
Wang, Mijia [1 ]
Wei, Zhendong [1 ]
Kong, Jixia [1 ]
Zhao, Haidong [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dalian 116023, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Neoadjuvant chemotherapy; Biomarkers; pCR; Tumor size change; TOPOISOMERASE-II-ALPHA; PATHOLOGICAL COMPLETE RESPONSE; HORMONE-RECEPTOR STATUS; PREDICTIVE MARKERS; PROGNOSTIC VALUE; HER2; RECEPTORS; KI-67; EXPRESSION; ER; IMPACT;
D O I
10.1186/s13000-024-01451-y
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background Accurately predicting the response to neoadjuvant chemotherapy (NAC) in breast cancer patients is crucial for guiding treatment strategies and enhancing clinical outcomes. Current studies have primarily focused on a limited set of biomarkers. More importantly, the results of many studies are in conflict. To address this, we conducted a comprehensive evaluation of the predictive value of a diverse range of clinically available molecular biomarkers in breast cancer, including HER2, ER, PR, TOPO II, EGFR, Ki67, CK5/6, AR, and p53. Additionally, we assessed changes in these biomarkers after NAC administration.Methods Our study involved 189 patients with invasive breast cancer who underwent NAC at our institute. We examined biomarker profiles in core-needle biopsies taken before NAC and in surgical specimens obtained after NAC. We examined the association between these biomarkers and NAC outcomes, focusing on two main aspects: the rate of pathological complete response (pCR) and the reduction in tumor size. We used Chi-square and Mann-Whitney U tests to compare biomarker status changes between pCR and non-pCR patients. Linear regression analysis was employed to evaluate the relationship between biomarker status and tumor shrinkage rate. Additionally, we compared the expression status of these biomarkers before and after NAC using Chi-square and Wilcoxon signed-rank tests.Results and conclusions Our results demonstrated significant differences in the expression levels of HER2, ER, PR, TOPO II, EGFR, and Ki67 between pCR and non-pCR patients, underscoring their potential as predictive markers for NAC outcomes. Importantly, our results have shed light on the contentious issue surrounding TOPO II in NAC outcome prediction. We have provided evidence that establishes a significantly positive association between TOPO II expression level and the pCR rate. Notably, tumor size was identified as a relevant predictive factor for achieving pCR. Regarding biomarker profiles, only Ki67 levels and TOPO II status exhibited changes following NAC, resolving previous controversies. While the ER and PR status remained unchanged, their expression values exhibited a slight but significant decrease post-NAC. Our results provide clarity and insights into the value and potential of using these biomarkers to predict NAC responses and prognosis in breast cancer patients.
引用
收藏
页数:10
相关论文
共 48 条
  • [31] The Role of Immunohistochemistry in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: An Old Tool With an Enduring Prognostic Value
    Sanchez-Munoz, Alfonso
    Maria Plata-Fernandez, Yessica
    Fernandez, Margarita
    Jaen-Morago, Ana
    Fernandez-Navarro, Monica
    de la Torre-Cabrera, Capilla
    Ramirez-Tortosa, Cesar
    Lomas-Garrido, Maria
    Llacer, Casilda
    Navarro-Perez, Victor
    Alba-Conejo, Emilio
    Sanchez-Rovira, Pedro
    [J]. CLINICAL BREAST CANCER, 2013, 13 (02) : 146 - 152
  • [32] Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy
    Shuai, Yanjie
    Ma, Li
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (01) : 29 - 33
  • [33] Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
    Spring, Laura M.
    Fell, Geoffrey
    Arfe, Andrea
    Sharma, Chandni
    Greenup, Rachel
    Reynolds, Kerry L.
    Smith, Barbara L.
    Alexander, Brian
    Moy, Beverly
    Isakoff, Steven J.
    Parmigiani, Giovanni
    Trippa, Lorenzo
    Bardia, Aditya
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (12) : 2838 - 2848
  • [34] Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy
    Tacca, Olivier
    Penault-Llorca, Frederique
    Abrial, Catherine
    Mouret-Reynier, Marie-Ange
    Raoelfils, Ines
    Durando, Xavier
    Achard, Jean-Louis
    Gimbergues, Pierre
    Cure, Herve
    Chollet, Phillipe
    [J]. ONCOLOGIST, 2007, 12 (06) : 636 - 643
  • [35] Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
    Tanner, Minna
    Isola, Jorma
    Wiklund, Tom
    Erikstein, Bjorn
    Kellokumpu-Lehtinen, Pirkko
    Malmstrom, Per
    Wilking, Nils
    Nilsson, Jonas
    Bergh, Jonas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2428 - 2436
  • [36] HER2 immunohistochemical scores provide prognostic information for patients with HER2-type invasive breast cancer
    Tsai, Yi-Fang
    Tseng, Ling-Ming
    Lien, Pei-Ju
    Hsu, Chih-Yi
    Lin, Yen-Shu
    King, Kuang-Liang
    Wang, Yu-Ling
    Chao, Ta-Chung
    Liu, Chun-Yu
    Chiu, Jen-Hwey
    Yang, Muh-Hwa
    [J]. HISTOPATHOLOGY, 2019, 74 (04) : 578 - 586
  • [37] Proliferation marker Ki-67 in early breast cancer
    Urruticoechea, A
    Smith, IE
    Dowsett, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7212 - 7220
  • [38] Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer
    van de Ven, S.
    Smit, V. T. H. B. M.
    Dekker, T. J. A.
    Nortier, J. W. R.
    Kroep, J. R.
    [J]. CANCER TREATMENT REVIEWS, 2011, 37 (06) : 422 - 430
  • [39] Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
    von Minckwitz, Gunter
    Untch, Michael
    Blohmer, Jens-Uwe
    Costa, Serban D.
    Eidtmann, Holger
    Fasching, Peter A.
    Gerber, Bernd
    Eiermann, Wolfgang
    Hilfrich, Joern
    Huober, Jens
    Jackisch, Christian
    Kaufmann, Manfred
    Konecny, Gottfried E.
    Denkert, Carsten
    Nekljudova, Valentina
    Mehta, Keyur
    Loibl, Sibylle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) : 1796 - 1804
  • [40] Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients
    Wachter, David L.
    Fasching, Peter A.
    Haeberle, Lothar
    Schulz-Wendtland, Ruediger
    Dimmler, Arno
    Koscheck, Thomas
    Renner, Stefan P.
    Lux, Michael P.
    Beckmann, Matthias W.
    Hartmann, Arndt
    Rauh, Claudia
    Schrauder, Michael G.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 287 (02) : 337 - 344